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Abstract 
 
Background: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and 
small family series.  Improved understanding of the clinical phenotype and genetic features 
associated with rare KCNE1 variants implicated in LQT5 was sought through an international 
multi-center collaboration. 
Methods: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive 
Type 2 Jervell and Lange-Nielsen syndrome (JLNS2, N = 19) were enrolled from 22 genetic 
arrhythmia clinics and 4 registries from 9 countries.  KCNE1 variants were evaluated for ECG 
penetrance (defined as QTc > 460ms on presenting ECG) and genotype-phenotype segregation.  
Multivariable Cox regression was used to compare the associations between clinical and genetic 
variables with a composite primary outcome of definite arrhythmic events, including appropriate 
implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death.  
Results: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 
genotype positive family members with presumed LQT5 and an additional 19 JLNS2 patients.  
Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in 
probands (476.9 + 38.6ms) compared to genotype positive family members (441.8 + 30.9ms, 
p<0.001).  ECG penetrance for heterozygous genotype positive family members was 20.7% 
(29/140).  A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous 
probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR]: 11.6, 
95% confidence interval [CI]: 2.6-52.2; p=0.001).  Event incidence did not differ significantly 
for JLNS2 patients relative to the overall heterozygous cohort (10.5% [2/19]; HR: 1.7, 95% CI: 
0.3-10.8, p=0.590).  The cumulative prevalence of the 32 KCNE1 variants in the Genome 
Aggregation Database (gnomAD), which is a human database of exome and genome sequencing 
data from now over 140,000 individuals, was 238-fold greater than the anticipated prevalence of 
all LQT5 combined (0.238% vs. 0.001%).   
Conclusions: The present study suggests that putative/confirmed loss-of-function KCNE1 
variants predispose to QT-prolongation, however the low ECG penetrance observed suggests 
they do not manifest clinically in the majority of individuals, aligning with the mild phenotype 
observed for JLNS2 patients.  
Key Words: long QT syndrome, genetics, penetrance, arrhythmia, sudden cardiac death 
 
Non-standard Abbreviations and Acronyms:  
long QT syndrome = LQTS 
sudden cardiac death = SCD 
Type 2 Jervell and Lange-Nielsen syndrome = JLNS2 
Genome Aggregation Database = gnomAD 
American College of Medical Genetics and Genomics = ACMG 
implantable cardioverter defibrillator = ICD 
aborted cardiac arrest = ACA 
Polymorphism Phenotyping v2 = PolyPhen-2 
Sorting Intolerant From Tolerant = SIFT 
Combined Annotation Dependent Depletion = CADD 
interquartile range = IQR 
confidence intervals = CI 
hazard ratio = HR. 
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Clinical Perspective 
 
What is new? 
• Rare loss-of-function KCNE1 variants are weakly penetrant and do not manifest with an 
LQTS phenotype in a majority of individuals. 
• QT-prolongation and arrhythmic risk associated with Type 2 Jervell and Lange-Nielsen 
syndrome is mild in comparison with the more malignant phenotype observed for Type 1 
Jervell and Lange-Nielsen syndrome. 
 
What are the clinical implications ? 
• All individuals possessing a rare loss-of-function KCNE1 variant should be counseled to 
avoid QT-prolonging medication and undergo a meticulous clinical evaluation to screen 
for an LQTS phenotype 
• In the absence of an LQTS phenotype, more intensive measures such as β-blockade and 
exercise restriction may not be merited.   
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Introduction 
Long QT syndrome (LQTS) is an inherited channelopathy characterized by impaired cardiac 
repolarization that confers an increased risk of syncope and sudden cardiac death (SCD) 
secondary to torsades de pointes.1  The prevalence of LQTS is approximately 1 in 2,000 and 17 
genes have been implicated in its pathogenesis, though the majority of cases stem from 
mutations within KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3), considered the major 
LQTS genetic subtypes.2–4  The KCNQ1 gene encodes the Kv7.1 α-subunit responsible for the 
slow component of the delayed rectifier potassium current (IKs), whereas the Kv11.1 α-subunit of 
the rapid component of the delayed rectifier potassium current (IKr) is encoded by KCNH2.5–7  
Loss-of-function mutations within these voltage-gated potassium channels impair ventricular 
repolarization during Phase 3 of the cardiac action potential leading to LQT1 and LQT2.8,9  
LQT5 is a minor LQTS genetic subtype accounting for approximately 1-2% of LQTS 
cases.  LQT5 develops secondary to loss-of-function variants within KCNE1, which encodes 
minK, a voltage-gated potassium channel β-subunit felt to primarily interact with the Kv7.1 α-
subunit responsible for IKs, though reports have also suggested a role for minK in IKr through an 
interaction with the Kv11.1 α-subunit.5,10–12  The most intensively investigated KCNE1 rare 
variant, p.Asp76Asn, has been implicated in both congenital and drug-induced forms of 
LQTS.10,13  The relative rarity of LQT5 has led to limited insight into its clinical and genetic 
attributes and management is often extrapolated from knowledge of the canonical LQT1-3 
subtypes.   
Recent work has revealed that loss-of-function variants in KCNE2, another voltage-gated 
potassium channel β-subunit, are more aptly characterized as arrhythmia predisposing variants or 
functional risk alleles, leading to recognition that LQT6 is not a monogenic form of LQTS and a 
 
D
ow
nloaded from
 http://ahajournals.org by on January 20, 2020
10.1161/CIRCULATIONAHA.119.043114 
5 
corresponding alteration to the treatment approach for individuals possessing these variants.14,15  
The KCNE2 and KCNE1 genes have many similarities, though only KCNE1 loss-of-function 
homozygotes and compound heterozygotes manifest with sensorineural deafness in association 
with QT-prolongation, referred to as Type 2 Jervell and Lange-Nielsen syndrome (JLNS2).16–18  
Notably, in contrast to the severe and often complete loss-of-function observed for pathogenic 
KCNQ1 and KCNH2 mutations, the reductions in cardiac potassium currents observed on 
experimental in vitro patch clamp analysis for KCNE2 and KCNE1 variants have been 
modest.10,19,20  
The growing recognition that each genetic LQTS subtype may require its own tailored 
approach to management led to the pursuit of an international multi-center collaboration to 
further define the clinical and genetic features of LQT5.21–25  
 
Methods 
Transparency and Openness Promotion 
Data that support the findings of this study are available from the corresponding author upon 
reasonable request. 
Study Population 
The study population consisted of 4 LQTS registries, including the Canadian LQTS registry, the 
Rochester (New York) LQTS registry, the Japanese LQTS registry, and the National Cardiac 
Inherited Disease Registry of New Zealand, along with 22 inherited arrhythmia clinics from 9 
countries.  Care was taken to ensure that no study participants were included twice through 
consultation with study investigators.  Inclusion criteria for living probands required the presence 
of a rare KCNE1 variant, defined as an allele frequency < 0.1% in the Genome Aggregation 
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Database (gnomAD; a database comprised of 141,456 individuals from multiple population-
based and disease-specific genetic cohort studies),26 and presence of a resting QTc >460ms on a 
surface ECG.  An allele frequency of < 0.1% was chosen, as this rate may be sufficiently rare to 
contribute to a low penetrant form of LQTS.  Genotype positive family members identified on 
cascade screening, which refers to clinical and genetic evaluation with variant-specific genetic 
testing of blood relatives at risk of being affected, were also included.   
Cases of SCD that remained unexplained following cardiac autopsy were eligible for 
inclusion when molecular autopsy identified a rare KCNE1 variant that had been observed in at 
least one living proband in our study that possessed a QTc > 460ms on ECG.  Homozygotes and 
compound heterozygotes of rare KCNE1 variants that exhibited sensorineural deafness consistent 
with JLNS2 were also eligible for the study.  All living probands presenting with an arrhythmic 
event were required to have undergone clinical testing with an ECG, exercise treadmill test, and 
echocardiogram, at minimum, and exhibit no evidence of another channelopathy or 
cardiomyopathy.  Probands entered into the study were also required to have undergone 
screening of all exons and associated exon-intron boundaries within the KCNQ1, KCNH2, 
SCN5A, KCNE1, and KCNE2 genes.    
Exclusion criteria for living probands and genotype positive family members consisted of 
a pathogenic or likely pathogenic mutation, as per American College of Medical Genetics and 
Genomics (ACMG) guidelines, in another LQTS gene and deceased probands were excluded 
when a pathogenic or likely pathogenic mutation was identified in a gene known to be causative 
for either a cardiac channelopathy or cardiomyopathy.27  Individuals possessing the known loss-
of-function, pro-arrhythmic risk allele KCNE1-p.Asp85Asn in isolation were not included due to 
its presence in 0.1-2.5% of the general population (depending on ancestry; 1.6% in European 
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ancestry subjects) and its being considered too common to function as a monogenic culprit for 
LQTS.15,28  
The following variables were collected retrospectively for all living probands and 
genotype positive family members: date of birth, date of initial presentation, reason for 
presentation, sex, familial status (proband versus family member), Bazett corrected QT-intervals 
(QTc) recorded on ECGs at initial presentation and during follow-up, date at the time of cardiac 
events (including presumed cardiac syncope, appropriate implantable cardioverter defibrillator 
[ICD] shock, aborted cardiac arrest [ACA] requiring resuscitation, and SCD with normal cardiac 
autopsy), activity at the time of the cardiac event, secondary QT stressors present at the time of 
the cardiac event (including QT prolonging medication, electrolyte abnormality, and heart 
block), and details of β-blocker usage, including dates of initiation and discontinuation, if 
applicable.  Genetic details of the KCNE1 variant, including the nucleotide and amino acid 
change, were obtained for each case.  
The study was performed as part of a protocol approved by the research ethics boards of 
Western University, London, Ontario, Canada and the collaborating institutions.  All study 
participants provided informed consent for their clinical and genetic data to be used for research. 
Assessment of ECG Penetrance and Genotype-Phenotype Segregation  
ECG penetrance was assessed in genotype positive family members.  Consistent with prior work, 
an electrocardiographically manifest (penetrant) LQTS phenotype was defined as a QTc value on 
the presenting ECG > 460ms.22  Evaluation for genotype-phenotype segregation was performed 
in each family in an effort to clarify the role of rare KCNE1 variants in predisposing to QT-
prolongation and was considered present if 2 or more individuals possessing the variant were 
phenotype positive. 
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Evaluation of KCNE1 Variants 
All KCNE1 variants included in the study were subjected to computer-based analyses and their 
prevalence in the general population and among individuals of European ancestry in isolation 
was assessed using gnomAD.26  Computer model predicting effects of mutations on protein 
function was performed using Polymorphism Phenotyping v2 (PolyPhen-2), Sorting Intolerant 
From Tolerant (SIFT), and Combined Annotation Dependent Depletion (CADD).29–31  Prior in 
vitro functional analyses of KCNE1 variants reported in the literature were reviewed.  Variants 
were presumed to be loss-of-function if they manifested with sensorineural deafness consistent 
with a JLNS2 phenotype when present in a homozygous or compound heterozygous state. 
Although variant classification was performed according to ACMG guidelines, this was 
ultimately deemed inappropriate secondary to the low level of penetrance observed for KCNE1 
variants; ACMG criteria have been designed for classification of highly penetrant variants.27 
Statistical Analysis 
Continuous variables are presented as means + standard deviation and those exhibiting normal 
and non-normal distributions were compared using Student’s t-test and the Wilcoxon rank-sum 
test, respectively.  Comparison of categorical values was performed using Fisher’s exact test.  
Cox proportional hazards models were used to estimate the associations between clinical and 
genetic variables and age at first presumed primary arrhythmic event (composite of presumed 
cardiac syncope, appropriate ICD shock, ACA, or SCD with normal autopsy; subsequently 
referred to as the composite arrhythmic outcome with syncope) and the first definite primary 
arrhythmic event (composite of appropriate ICD shock, ACA, or SCD with normal autopsy; 
subsequently referred to as the composite arrhythmic outcome without syncope) among 
heterozygotes possessing rare KCNE1 variants and JLNS2 patients.   
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Variables evaluated in both uni-/multivariable analyses included familial status (proband 
versus family member), sex, QTc on initial presenting ECG, β-blocker therapy, and missense 
variant location (extracellular, transmembrane, intracellular) in the KCNE1-encoded β-subunit.  
The QTc on the initial presenting ECG was treated as a categorical variable divided into tertiles 
(<470 ms, > 470 ms but < 500 ms, and > 500 ms).  Cumulative years on β-blocker therapy was 
treated as a time-dependent covariable in order to account for patients starting and stopping 
treatment throughout their lifetime and enabled comparison of event rates during time on β-
blocker therapy relative to time off β-blocker therapy.  Risk of arrhythmic events was also 
evaluated based on KCNE1-p.Asp76Asn variant status (KCNE1-p.Asp76Asn carriers versus 
carriers of another KCNE1 variant).  Robust standard errors were used to account for familial 
relatedness.  Due to minimal missing data, which only consisted of ECG values and age at LQTS 
diagnosis among 2 SCD cases identified to possess KCNE1 variants on molecular autopsy, 
complete case analysis was used.  Two-tailed p-values < 0.05 were considered statistically 
significant.  Statistical analyses were performed using Stata version 16 (College Station, TX, 
USA).  
 
Results 
Study Population 
Eighty-nine probands heterozygous for a rare KCNE1 variant in the setting of a phenotype 
compatible with LQTS and 140 genotype positive family members were enrolled into the study 
(Table 1).  The mean age at the time of first ECG was 25.4 + 19.7 years and 61.6% were female.  
The mean QTc on the presenting ECG among probands was significantly longer relative to 
genotype positive family members (476.9 + 38.6ms vs. 441.8 + 30.9ms, p< 0.001).  β-blocker 
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therapy was used at some point in 78.7% of probands and 55.0% of genotype positive family 
members.  A total of 41.6% of probands experienced a presumed cardiac event during their 
lifetime, defined as presumed cardiac syncope, appropriate ICD shock, ACA, or SCD, compared 
to only 5.7% of KCNE1 variant-positive family members (p<0.001).  The number of individuals 
that experienced each of these events is provided in Table 1.  Within the overall heterozygous 
cohort, the median ages of onset of the composite arrhythmic outcomes with and without 
syncope were 23.5 (interquartile range [IQR]: 14.2-43.4) and 27.0 (15.2-45.4) years, 
respectively. 
The KCNE1-p.Asp76Asn variant was present in 98 of 229 heterozygous individuals 
(42.8%) and the mean QTc among carriers (455.1 + 35.5ms) was similar to the mean QTc value 
observed among the remaining individuals in the heterozygous cohort (455.9 + 40.2ms, p = 
0.873).  An additional 19 JLNS2 individuals, including 15 homozygotes and 4 compound 
heterozygotes, were enrolled into the study and their clinical features are reported in Table 1.  
The composite arrhythmic outcome with syncope was experienced in a total of 13.3% (2/15) of 
homozygotes and 50% (2/4) of compound heterozygotes.  
Among KCNE1 heterozygotes, only 2 genotype positive family members had definite 
arrhythmic events; their details are provided in the Online Supplement.  The median age at the 
time of last follow up for the overall heterozygous cohort was 27.3 years (IQR: 15.2-45.6).    
Disease Penetrance and Genotype-Phenotype Segregation  
Disease penetrance was assessed in genotype positive family members based on the definition 
for an electrocardiographically manifest LQTS phenotype being a QTc value > 460ms on 
presenting ECG.  The overall penetrance was 20.7% (29/140).  Penetrance values for each 
individual KCNE1 variant possessed in a heterozygous state by a family member are illustrated 
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in Figure 1.  Among the 10 KCNE1 variants possessed by > 3 individuals, penetrance values 
ranged from 0% (p.Asn5Ter and p.Thr7Ile) to 75% (p.Gly55Ser).  The KCNE1-p.Asp76Asn 
variant, present in a heterozygous state in 63 family members, exhibited an overall penetrance of 
17.5%.  Among JLNS2 patients, the electrocardiographic penetrance was 66.7% (10/15) in 
homozygotes and 75% (3/4) in compound heterozygotes. 
 Genotype-phenotype segregation was assumed to be present if at least 2 individuals in a 
single family were phenotype positive.  Thirteen of 52 (25%) families with at least 2 genotype 
positive individuals possessed evidence of genotype-phenotype segregation (Supplemental 
Table 1).  Genotype-phenotype segregation was observed for 8 KCNE1 variants (KCNE1-
p.Gln22Ter, -p.Ser28Leu, -p.Tyr46Cys, -p.Gly55Ser, -p.Arg67Cys, p.Arg67His, -p.Asp76Asn, 
and -p.Val109Ile; Supplemental Table 1). 
Arrhythmic Risk Associations 
Univariable Analyses 
Probands possessing a rare KCNE1 variant had a 6.6-fold (95% confidence intervals [CI]: 3.6-
12.3, p< 0.001) higher hazard of experiencing the composite arrhythmic outcome with syncope 
relative to genotype positive family members (Figure 2A and Table 2) and a 11.2-fold (95% CI: 
2.9-43.2, p<0.001) higher hazard of the composite arrhythmic outcome without syncope (Figure 
2B and Table 2).  Evaluation of QTc values on presenting ECG revealed that the upper 2 tertiles 
were both associated with a higher risk of the composite arrhythmic outcome with syncope, 
whereas only the QTc > 500ms tertile exhibited a statistically significant association for the 
composite arrhythmic outcome without syncope, respectively (Table 2 and Supplemental 
Figure 1).  Neither sex (Figure 3), nor β-blocker therapy, nor missense variant location within 
the KCNE1-encoded Kv7.1 β subunit (Supplemental Figure 2) were associated with an altered 
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risk of the composite arrhythmic outcomes on univariable analysis (Table 2).  The arrhythmic 
risk associated with the p.Asp76Asn variant, the most prevalent KCNE1 variant in the cohort 
carried by 42.8% of heterozygotes, did not differ statistically relative to the collective remainder 
of the KCNE1 variants evaluated (Supplemental Figure 3).       
 Univariable analyses for probands in isolation revealed measures of association that were 
generally consistent with the overall heterozygous cohort with no point estimates that extended 
beyond the 95% CI boundaries (Supplemental Table 2). 
Multivariable Analysis 
A multivariable Cox regression model was constructed including the variables for familial status, 
sex, QTc tertile on presenting ECG, β-blocker therapy, and location of the missense variant 
within the KCNE1-encoded Kv7.1 β subunit.  Following adjustment, familial status was the only 
predictor that continued to exhibit a statistically significant association for the arrhythmic 
outcomes (Table 2).  Similar results were obtained for probands in isolation with no point 
estimates that extended beyond the 95% CI boundaries for the overall heterozygous cohort 
(Supplemental Table 2). 
JLNS2 Arrhythmic Outcomes 
The mean QTc values on presenting ECG in JLNS2 patients trended towards being longer 
relative to individuals possessing a KCNE1 variant in a heterozygous state, but did not reach 
statistical significance (471.1 + 43.5ms versus 455.6 + 38.2ms, p = 0.050) (Table 1).  JLNS2 
patients had event rates that also did not exhibit statistically significant differences relative to 
KCNE1 heterozygotes for the composite arrhythmic outcomes including syncope (hazard ratio 
[HR] = 1.2, 95% CI 0.2-6.4, p= 0.800, Figure 4A) and excluding syncope (HR = 1.7, 95% CI 
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0.3-10.8, p= 0.590, Figure 4B).  The median age at the time of last follow up for the JLNS2 
cohort was 27.2 years (IQR: 15.8-38.0).    
Secondary QT Stressors and Triggers for Cardiac Events 
A total of 62 cardiac events were experienced among the entire cohort during a collective 7,844 
patient years beginning from birth.  Three events were reported to have occurred in the setting of 
a QT-prolonging medication, 1 in the context of a severe electrolyte abnormality, and 1 was 
attributed to torsades de pointes in the setting of complete heart block.  No secondary QT-
prolonging stressors were identified in association with the remaining events.  Activities reported 
at the time of events included awake at rest in 37 (60.0%), exertion in 17 (27.4%), auditory 
stimuli in 2 (3.2%), post-exertion in 1 (1.6%), sleep in 1 (1.6%), and the activity at the time of 
the event was unknown in 4 (6.5%).  
Evaluation of KCNE1 Variants 
Population Allele Frequencies 
Among the 32 KCNE1 variants possessed by the study participants, 22 were observed in 
gnomAD, with individual allele frequencies ranging up to 0.02094% for the Thr10Met variant 
(0.02134% when restricted to European ancestry; Supplemental Table 3).  The collective 
prevalence of these variants in the overall gnomAD cohort was 0.238% and 0.169% among the 
European ancestry subgroup.  Based on the assumptions that the prevalence of LQTS is 0.05% 
and LQT5 accounts for 2% of LQTS, its prevalence is estimated at 0.001%.  The collective 
prevalence of KCNE1 variants implicated in LQT5 is 238-fold the anticipated prevalence of 
LQT5 when the overall gnomAD cohort is considered and 169-fold when the analysis is 
restricted to individuals of European ancestry.   
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Eight of the 32 KCNE1 variants were observed in JLNS2, confirming their status as loss-
of-function given their being causative for sensorineural deafness (Supplemental Table 3).  The 
collective prevalence of KCNE1 variants identified in the context of JLNS2 in the overall 
gnomAD cohort was 0.0162% and 0.0240% among Europeans.    
Computer-Based and Previously Reported In Vitro Analyses 
Computer-based analysis of KCNE1 variants possessed by study participants was performed 
using PolyPhen-2, SIFT, and CADD (Supplemental Table 3).  PolyPhen-2 and SIFT both 
identified 14 of 24 missense variants as probably/possibly damaging or damaging, respectively.  
A total of 18 of 27 single nucleotide variants had a CADD score greater than 20, predicting their 
being among the top 1% of most damaging variants within the genome.31  Classification of the 
variants using the 2015 ACMG guidelines identified 3 as pathogenic, 5 as likely pathogenic, 17 
as a variant of unknown significance, and 7 as likely benign (Supplemental Table 3).  
Assignment of likely benign status to 7 variants was primarily driven by their minor allele 
frequencies being greater than the anticipated prevalence of LQT5 (0.001%), which is not 
considered appropriate when variant penetrance is anticipated to be low.  On review of the 
literature, in vitro patch-clamping analysis using heterologous expression of mutant KCNE1 in 
association with wild-type KCNQ1 had been performed for only 4 of 25 KCNE1 missense 
variants (Supplemental Table 3) and each was consistent with a loss-of-function.10,19,20   
 
Discussion 
This international multicenter study represents the first large-scale evaluation of rare KCNE1 
variants implicated as monogenic culprits for LQTS.  Their low ECG penetrance in family 
members, coupled with their excess prevalence in gnomAD, suggests that loss-of-function 
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KCNE1 variants do not manifest clinically in a majority of individuals.  The benign phenotype 
observed in the vast majority of genotype positive family members strongly suggests that loss-
of-function KCNE1 variants require additional genetic and/or non-genetic factors to manifest 
with a positive LQTS phenotype.  However in contrast to KCNE214, QT-prolongation and 
clinical events occurred in the overwhelming majority of individuals in the absence of an 
identifiable QT prolonging stressor, suggesting that LQT5 should be viewed as a low penetrant 
primary arrhythmic condition rather than an exclusively provoked syndrome.  These findings, 
which align with the conclusions drawn for KCNE1 from the recent Clinical Genome Resource 
Consortium reappraisal of LQTS genes, have important clinical implications for probands and 
genotype positive family members.32  
Evaluation of arrhythmic events among probands initially suggested that LQT5 may be a 
highly malignant disorder, however mirroring prior work in LQTS, the striking event rate 
observed among probands differed dramatically relative to the findings among genotype positive 
family members.33  The contrasting arrhythmic profiles of probands and genotype positive 
family members, coupled with clinical and genetic evidence suggesting KCNE1 variants do not 
manifest clinically in the majority of individuals, strongly suggests that the high event rate 
observed among LQT5 probands was secondary to selection bias.  Although operative in all 
forms of LQTS, the impact of selection bias is expected to be more extreme for low penetrant 
variants when the contribution of genomic background and environmental influences to 
arrhythmic events and QT prolongation is anticipated to be much greater.  This concept is 
effectively illustrated by a recent study that identified hazard ratios ranging from 2.48- to 3.21 
for a composite outcome of syncope, ACA, or SCD among probands relative to family members 
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in the major LQTS genetic subtypes (1-3), in comparison to the unadjusted 6.6-fold increased 
hazard ratio reported here for LQT5.34  
 Aside from familial status, no other intrinsic clinical or genetic factors, including QTc on 
presenting ECG, sex, β-blocker therapy, and missense variant location, were associated with an 
altered risk of events on multivariable analyses (Table 2).  Notably, only 64.2% of individuals 
were treated with β-blocker during their lifetime and the mean QTc of those administered β-
blockade was 464.4 + 39.0 ms in comparison with a mean value of 439.4 + 30.8 ms for those not 
treated (p<0.001).  These findings suggest that patients with milder phenotypes were not treated, 
which is anticipated to lead to biased measures of association secondary to confounding by 
indication.  It is possible that confounding by indication, coupled with the low event rate, may 
have led to the lack of an apparent protective effect with β-blocker.  
Although the findings from the current study serve as strong evidence that many KCNE1 
variants are insufficient in isolation to cause LQTS, it could be argued that only a minority of 
these variants have undergone functional work and hence the physiological relevance for the 
majority is unclear.  Eight of the 32 variants were observed among cases of JLNS2 providing 
definitive evidence for their being loss-of-function.  Penetrance of these variants was 15.7% 
among family members, which was consistent with findings from the overall sample (20.7%).  In 
addition, QTc values and event rates among study participants possessing the most prevalent 
KCNE1 variant (p.Asp76Asn), known to be loss-of-function and present in 98 of the 229 
heterozygous individuals, were consistent with those from the remainder of the cohort 
(Supplemental Figure 2).10,19  
Attempted evaluation of the KCNE1 variants using ACMG criteria was ultimately 
deemed inappropriate due to their low penetrance given that ACMG criteria are tailored for 
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highly penetrant variants.27  Notably, the KCNE1-p.Asp76Asn variant has a prevalence among 
individuals with European ancestry of 0.02212%, which exceeds the anticipated prevalence of 
LQT5 (0.001%) by >22-fold.  A greater than expected allele frequency for the disorder being 
evaluated is considered a strong ACMG criterion for classifying a variant as benign.  Although 
the p.Asp76Asn variant had sufficient additional supporting evidence to still receive a likely 
pathogenic designation, 7 KCNE1 variants were demoted to likely benign status primarily owing 
to their prevalence being greater than anticipated for LQT5 (Supplemental Table 3).  In the 
collective view of the investigators, given that KCNE1-p.Asp76Asn is an established genetic 
culprit for LQT5, it is not felt that demotion of other variants with similar allele frequencies to 
likely benign status on the basis of their apparent excess prevalence is appropriate.15  
The study also builds upon prior work and provides additional insight into the JLNS2 
phenotype.18  In contrast to JLNS1, an autosomal recessive condition secondary to homozygous 
or compound heterozygous KCNQ1 loss-of-function mutations and characterized by marked QT 
prolongation and a highly malignant arrhythmic phenotype, the phenotype of JLNS2 appeared 
surprisingly mild, which aligns with earlier work.18  Although the apparent lack of an effect on 
phenotypic severity for increasing gene dosage may be secondary to inadequate power given that 
only 19 JLNS2 patients were included in the study, the finding that JLNS2 has a relatively mild 
phenotype lends further support to dysfunction of the KCNE1-encoded β-subunit often being 
clinically concealed..   
Although a functional copy of KCNE1 is necessary for sensorineural hearing, the findings 
from this study suggest that the KCNE1-encoded β-subunit may either exert a modest role in 
cardiac repolarization or, alternatively, the heart, in contrast to the inner ear, may have 
established a redundancy for β-subunits that allows for effective compensation in response to the 
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loss of one constituent.  The notion that a single β-subunit may be able to interact 
interchangeably with multiple pore forming α-subunits is alluded to by evidence that minK not 
only contributes to IKs, but also IKr through an interaction with the Kv11.1 α-subunit.5,11,12  
Whereas possessing a pathogenic mutation causative for the major genetic LQTS 
subtypes results in a diagnosis of LQTS and most often triggers initiation of a β-blocker 
regardless of phenotype35, evidence from the current study suggests that an alternative approach 
to management for individuals possessing a KCNE1 rare variant in the absence of an LQTS 
phenotype may be desired.  While it is felt that all individuals possessing a loss-of-function 
KCNE1 variant should be advised to avoid QT-prolonging drugs13, in the presence of a normal 
phenotype intensive measures such as β-blockade and exercise restriction may not be merited.  
Although a protective effect of β-blockade was not observed in the study, given the potential 
limitations highlighted above that may have led to both biased and underpowered results, it is felt 
that β-blocker therapy should still be recommended in the presence of a positive LQTS 
phenotype.  Due to the presence of study participants that experienced presumed arrhythmic 
events despite QTc values considered within normal limits on presenting ECG, highlighting the 
limitations of a single ECG to assess disease penetrance, it is advocated that all individuals 
possessing true loss-of-function variants be followed for serial monitoring of QTc values.  
Routine use of cascade screening for these variants is also advocated given their potential to 
manifest with a malignant LQTS phenotype, as highlighted by the natural history of the probands 
in the study. 
Limitations 
Although the largest dedicated evaluation for rare KCNE1 variants to date, the study may be 
underpowered to detect statistically significant associations between relevant clinical and genetic 
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factors and arrhythmic risk.  As an observational study, it is also vulnerable to various 
unavoidable forms of bias.  The cohort consisted of probands referred to specialized inherited 
arrhythmia clinics due to worrisome clinical findings and likely led to selection of a malignant 
subset of KCNE1 heterozygotes and a correspondingly inflated arrhythmic event rate.  In 
addition, evaluation for a potential protective effect of β-blocker therapy will unavoidably be 
biased secondary to confounding by indication.  
Conclusions 
The present study reveals that KCNE1 loss-of-function variants are weakly penetrant and 
individuals manifesting with an LQTS phenotype in the presence of a loss-of-function KCNE1 
variant likely possess additional genetic or environmental factors that predispose to QT 
prolongation.  In contrast to KCNE2, the overwhelming majority of probands and genotype 
positive family members manifesting with QT-prolongation and arrhythmic events did so in the 
absence of a QT-prolonging stressor suggesting that LQT5 should be viewed as a low penetrant 
primary arrhythmic condition rather than an exclusively provoked syndrome.  Following 
identification of a rare KCNE1 loss-of-function variant, clinical management should consist of 
meticulous evaluation for an LQTS phenotype and counselling regarding the avoidance of QT 
prolonging drugs.   
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Table 1. Clinical Features of Probands and Genotype Positive Family Members Possessing Rare 
KCNE1 Variants 
 
 LQT5  
p value* 
JLNS2 
Clinical Variable Overall 
n = 229 
Probands 
n = 89 
Genotype +ve FM 
n = 140 
 
n = 19 
Age at First ECG (years) 25.4 (19.7) 26.8 (19.2) 24.5 (19.9) 0.174 14.6 (14.0) 
Female (%) 141 (61.6) 59 (66.3) 82 (58.6) 0.211 9 (47.4) 
European Ancestry (%) 219 (95.6) 83 (93.3) 136 (97.1) 0.016 16 (84.2) 
QTc on Presenting ECG (ms) 455.6 (38.2) 476.9 (38.6) 441.8 (30.9) <0.001 471.1 (43.5) 
Males 448.5 (36.2) 469.3 (38.2) 437.7 (30.2) <0.001 468.9 (53.5) 
Females 460.1 (38.8) 480.8 (38.6) 444.8 (31.3) <0.001 473.6 (32.0) 
Atrial Fibrillation 7 (3.1) 6 (6.7) 1 (0.7) 0.017 0 (0) 
Treatment      
β-Blocker 147 (64.2) 70 (78.7) 77 (55.0) 0.001 8 (42.1) 
LCSD 5 (2.2) 2 (2.2) 3 (2.1) 1.000 1 (5.3) 
ICD 28 (12.2) 23 (25.8) 5 (3.6) <0.001 0 (0) 
Cardiac Event      
Syncope 31 (13.5) 25 (28.1) 6 (4.2) <0.001 3 (15.8) 
Appropriate ICD Shock 4 (1.8) 3 (3.4) 1 (0.7) 0.304 0 (0) 
Aborted Cardiac Arrest 12 (5.2) 12 (13.5) 0 (0) <0.001 1 (5.3) 
Sudden Cardiac Death 4 (1.8) 3 (3.4) 1 (0.7) 0.304 1 (5.3) 
CAO with Syncope 45 (19.7) 37 (41.6) 8 (5.7) <0.001 4 (21.1) 
CAO Without Syncope 17 (7.4) 15 (16.9) 2 (1.4) <0.001 2 (10.5) 
Data are n (%) or mean (SD). *p-value compares LQT5 probands and family members.  LQT5 = Type 5 
Long QT syndrome, JLNS2 = Type 2 Jervell and Lange-Nielsen Syndrome, Genotype +ve FM = 
genotype positive family members, ms = milliseconds, LCSD = left cardiac sympathetic denervation, ICD 
= implantable cardioverter defibrillator, CAO = composite arrhythmic outcome 
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Table 2. Association of Clinical and Genetic Variables with Cardiac Events Among Individuals Heterozygous for Rare KCNE1 
Variants 
 
Clinical and Genetic 
Variables 
Composite of Syncope,  
Appropriate ICD Shock, ACA, SCD 
Composite of 
Appropriate ICD Shock, ACA, SCD 
Unadjusted HR  
(95% CI) 
p-value Adjusted HR 
(95% CI) 
p-value Unadjusted HR  
(95% CI) 
p-value Adjusted HR 
(95% CI) 
p-value 
Familial Status  6.6 (3.5-12.3) <0.001 4.7 (1.9-11.7) <0.001 11.2 (2.9-43.2) <0.001 11.6 (2.6-52.2) 0.001 
Female Sex 1.9 (0.9-3.8) 0.08 0.9 (0.4-1.8) 0.75 1.8 (0.5-6.6) 0.39 0.4 (0.1-1.3) 0.13 
QTc tertiles (ms)  <470 Reference - - - Reference - - - 
470-500 3.6 (1.8-7.2) <0.001 1.8 (0.8-4.4) 0.17 2.1 (0.6-7.3) 0.23 0.9 (0.2-3.9) 0.90 
>500 3.4 (1.5-7.9) 0.004 1.3 (0.4-4.6) 0.65 7.9 (2.4-25.3) <0.001 3.3 (0.7-15.7) 0.13 
Time on β-Blocker*  1.0 (0.9-1.2) 0.53 1.0 (0.9-1.2) 0.69 1.0 (0.9-1.1) 0.75 1.0 (0.9-1.1) 0.80 
Variant Location         
Extracellular Reference - - - Reference - - - 
Transmembrane 1.6 (0.4-6.9) 0.51 1.4 (0.4-5.4) 0.65 1.1 (0.1-10.0) 0.93 0.5 (0.1-5.0) 0.55 
Intracellular 0.9 (0.3-2.9) 0.88 0.7 (0.2-2.2) 0.53 0.5 (0.1-2.7) 0.44 0.3 (0.1-1.8) 0.21 
* β-blocker treated as a time dependent covariable.  ICD = implantable cardioverter defibrillator, ACA = aborted cardiac arrest, SCD = sudden 
cardiac death, HR = hazard ratio, CI = confidence interval, ms = milliseconds. 
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Figure Legends 
 
Figure 1. ECG Penetrance of Rare KCNE1 Variants.  Penetrance is defined as a QTc > 460ms 
on their presenting ECG. (N) indicates the number of individuals with the KCNE1 variant 
 
Figure 2. Arrhythmic Events Among Probands and Genotype Positive Family Members 
Possessing a Rare KCNE1 Variant.  Outcomes of (A) Syncope, Appropriate ICD Shock, ACA, or 
SCD and (B) Appropriate ICD Shock, ACA, or SCD. ICD = implantable cardioverter-
defibrillator, ACA = aborted cardiac arrest, SCD = sudden cardiac death, ref = reference, HR = 
hazard ratio, CI = confidence intervals. 
 
Figure 3. Arrhythmic Events Among Males and Females Possessing a Rare KCNE1 Variant.  
Outcomes of (A) Syncope, Appropriate ICD Shock, ACA, or SCD and (B) Appropriate ICD 
Shock, ACA, or SCD. ICD = implantable cardioverter-defibrillator, ACA = aborted cardiac 
arrest, SCD = sudden cardiac death, ref = reference, HR = hazard ratio, CI = confidence 
intervals. 
 
Figure 4. Arrhythmic Events Among Type 2 Jervell and Lange-Nielsen Syndrome Patients and 
KCNE1 Heterozygotes.  Outcomes of (A) Syncope, Appropriate ICD Shock, ACA, or SCD and 
(B) Appropriate ICD Shock, ACA, or SCD. JLNS2 = Type 2 Jervell and Lange-NieIsen 
syndrome, ICD = implantable cardioverter-defibrillator, ACA = aborted cardiac arrest, SCD = 
sudden cardiac death, ref = reference, HR = hazard ratio, CI = confidence intervals. 
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